MX2020001272A - Anticuerpos dirigidos contra interleucina-33 (il-33). - Google Patents

Anticuerpos dirigidos contra interleucina-33 (il-33).

Info

Publication number
MX2020001272A
MX2020001272A MX2020001272A MX2020001272A MX2020001272A MX 2020001272 A MX2020001272 A MX 2020001272A MX 2020001272 A MX2020001272 A MX 2020001272A MX 2020001272 A MX2020001272 A MX 2020001272A MX 2020001272 A MX2020001272 A MX 2020001272A
Authority
MX
Mexico
Prior art keywords
chain polypeptide
directed against
antibodies directed
against interleukin
binding agent
Prior art date
Application number
MX2020001272A
Other languages
English (en)
Inventor
Robert A Horlick
David J King
Andrew John Mcknight
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of MX2020001272A publication Critical patent/MX2020001272A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a un polipéptido de cadena pesada de inmunoglobulina aislado y un polipéptido de cadena ligera de inmunoglobulina aislado que se enlazan a interleucina-33 (IL-33). La invención proporciona un agente de enlace a IL-33 que comprende el polipéptido de cadena pesada de inmunoglobulina y el polipéptido de cadena ligera de inmunoglobulina anteriormente mencionados. La invención también proporciona vectores, composiciones, y métodos relacionados al uso del agente de enlace a IL-33 para tratar un trastorno en un mamífero que responde a inhibición de IL-33.
MX2020001272A 2014-01-10 2016-07-08 Anticuerpos dirigidos contra interleucina-33 (il-33). MX2020001272A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461925946P 2014-01-10 2014-01-10

Publications (1)

Publication Number Publication Date
MX2020001272A true MX2020001272A (es) 2020-07-20

Family

ID=53524474

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009047A MX2016009047A (es) 2014-01-10 2015-01-09 Anticuerpos dirigidos contra interleucina-33 (il-33).
MX2020001272A MX2020001272A (es) 2014-01-10 2016-07-08 Anticuerpos dirigidos contra interleucina-33 (il-33).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016009047A MX2016009047A (es) 2014-01-10 2015-01-09 Anticuerpos dirigidos contra interleucina-33 (il-33).

Country Status (14)

Country Link
US (3) US10059764B2 (es)
EP (1) EP3092253B1 (es)
JP (2) JP2017503506A (es)
KR (1) KR102446386B1 (es)
CN (1) CN106103480B (es)
AU (1) AU2015204674B2 (es)
BR (1) BR112016016020B1 (es)
CA (1) CA2936366A1 (es)
ES (1) ES2866935T3 (es)
MX (2) MX2016009047A (es)
NZ (1) NZ722445A (es)
RU (2) RU2693084C2 (es)
SG (2) SG11201605580RA (es)
WO (1) WO2015106080A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2371865T3 (en) 2006-04-07 2017-10-23 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (HPTP-β) and uses thereof
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9637535B2 (en) 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
BR112016013347B1 (pt) 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
AU2015204674B2 (en) 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
EP3402521A4 (en) * 2016-01-14 2019-11-20 AnaptysBio, Inc. INHIBITION OF ALLERGIC REACTION USING AN IL-33 INHIBITOR
CN109415436A (zh) * 2016-04-27 2019-03-01 辉瑞公司 抗il-33抗体及其组合物、方法及用途
KR20190031246A (ko) * 2016-07-20 2019-03-25 에르피오 세러퓨틱스 인코포레이티드 VE-PTP (HPTP-β)를 표적으로 하는 인간화된 단클론성 항체
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
BR112019012691A2 (pt) 2016-12-19 2019-11-19 Fundacio Privada Inst Catalana De Recerca I Estudis Avancats anticorpos contra a lif e seus usos
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
CN116715775A (zh) 2017-02-10 2023-09-08 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途
CN110431240A (zh) 2017-04-13 2019-11-08 雷杰纳荣制药公司 在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制
TWI825025B (zh) 2017-08-31 2023-12-11 日商田邊三菱製藥股份有限公司 包含il-33拮抗劑的子宮內膜異位症治療劑
EP3694877A1 (en) 2017-10-09 2020-08-19 AnaptysBio, Inc. Anti-il-33 therapy for atopic dermatitis
AU2019218128A1 (en) 2018-02-09 2020-09-17 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2019183639A1 (en) * 2018-03-23 2019-09-26 Anaptysbio, Inc. Inhibition of allergic reaction to peanut allergen using an il-33 inhibitor
IL307286A (en) 2018-04-11 2023-11-01 Regeneron Pharma Methods and preparations for quantification of IL-33
TW202021983A (zh) 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
TW202134261A (zh) 2019-11-04 2021-09-16 英商梅迪繆思有限公司 使用il-33拮抗劑之方法
JP2023501316A (ja) 2019-11-04 2023-01-18 メドイミューン・リミテッド 腎機能障害を治療するための抗ｉｌ－３３治療薬
JPWO2021157619A1 (es) 2020-02-05 2021-08-12
JP2023517345A (ja) 2020-03-13 2023-04-25 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
CA3176571A1 (en) 2020-04-06 2021-10-14 Medimmune Limited Treating acute respiratory distress syndrome with il-33 axis binding antagonists
CA3181765A1 (en) 2020-05-11 2021-11-18 Medimmune Limited Formulations of anti-il-33 antibodies
US20210380721A1 (en) * 2020-06-01 2021-12-09 University Of Kentucky Research Foundation Compounds and methods for use in connection with opioid use disorders
US20230255954A1 (en) * 2020-07-07 2023-08-17 The General Hospital Corporation Interleukin 33 (il-33) inhibition for treatment of cancer, fibrosis and inflammation
KR20220022226A (ko) * 2020-08-18 2022-02-25 성균관대학교산학협력단 Il-33 항체 또는 이의 항원 결합 단편
CN114249825A (zh) * 2020-09-25 2022-03-29 三生国健药业（上海）股份有限公司 结合人il-33的抗体、其制备方法和用途
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
WO2024038185A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Method of selecting patients for treatment with an il-33 axis antagonist

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
EP1461423B1 (en) 2001-12-03 2008-05-14 Amgen Fremont Inc. Antibody categorization based on binding characteristics
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
WO2007011941A2 (en) * 2005-07-18 2007-01-25 Amgen Inc. Human anti-b7rp1 neutralizing antibodies
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
EP3339445B1 (en) 2006-09-08 2020-07-15 AbbVie Bahamas Ltd. Interleukin -13 binding proteins
US20090075378A1 (en) 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
WO2008132709A1 (en) 2007-04-26 2008-11-06 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Products for altering il-33 activity and methods therefor
CA2686683A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc Il-33 in inflammatory disease
US8278065B2 (en) * 2008-06-30 2012-10-02 Morphotek, Inc. Polynucleotides encoding anti-GD2 antibodies
PE20120586A1 (es) 2009-01-29 2012-06-17 Abbott Lab Proteinas de union a il-1
WO2011031600A1 (en) 2009-09-10 2011-03-17 Schering Corporation Use of il-33 antagonists to treat fibrotic disease
EP2488202B1 (en) 2009-10-15 2015-07-08 Avaxia Biologics, Inc. Antibody therapeutics with local activity in the digestive tract
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
NZ608206A (en) * 2010-08-16 2015-02-27 Amgen Inc Antibodies that bind myostatin, compositions and methods
CN103379917B (zh) 2010-11-01 2016-10-12 梅琳塔治疗公司 药物组合物
AR084342A1 (es) 2010-12-16 2013-05-08 Genentech Inc Diagnostico y tratamientos relacionados con la inhibicion de th2
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
WO2013063095A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
CA2853719A1 (en) 2011-10-27 2013-05-02 Nkt Therapeutics Inc. Humanized antibodies to inkt
EP2817417B1 (en) 2012-02-24 2017-10-25 Children's Hospital Medical Center Esophageal microrna expression profiles in eosinophilic esophagitis
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
BR112015001859A2 (pt) 2012-07-31 2017-07-04 Novartis Ag tratamento de inflamação utilizando serelaxina
US20150250808A1 (en) 2012-10-15 2015-09-10 Vojo P. Deretic Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
WO2014090800A1 (en) 2012-12-10 2014-06-19 Vib Vzw Novel interleukin-33 inhibitors
KR101780575B1 (ko) 2013-02-14 2017-09-21 건국대학교 산학협력단 신규한 인터루킨-33 수용체와 결합 단백질 조성물 및 그 용도
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9637535B2 (en) 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
HUE042607T2 (hu) 2013-08-12 2019-07-29 Astrazeneca Ab Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával
KR101567758B1 (ko) 2013-10-17 2015-11-11 인하대학교 산학협력단 항-Siglec-8 항체 또는 항-Siglec-F 항체, 및 항-IL-33 항체를 포함하는 알러지 질환의 예방 또는 치료용 조성물
BR112016008694A2 (pt) 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
BR112016013347B1 (pt) 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
AU2015204674B2 (en) 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
US10040859B2 (en) 2014-04-21 2018-08-07 The Children's Hospital Of Philadelphia Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
US10500273B2 (en) 2015-03-02 2019-12-10 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
MX2018004170A (es) 2015-10-06 2018-06-06 Regeneron Pharma Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
EP3402521A4 (en) 2016-01-14 2019-11-20 AnaptysBio, Inc. INHIBITION OF ALLERGIC REACTION USING AN IL-33 INHIBITOR

Also Published As

Publication number Publication date
AU2015204674A1 (en) 2016-08-25
US20210040198A1 (en) 2021-02-11
BR112016016020A2 (pt) 2018-05-22
WO2015106080A2 (en) 2015-07-16
US20180346562A1 (en) 2018-12-06
MX2016009047A (es) 2017-04-13
US10836820B2 (en) 2020-11-17
EP3092253A2 (en) 2016-11-16
CN106103480A (zh) 2016-11-09
WO2015106080A3 (en) 2015-09-11
SG11201605580RA (en) 2016-10-28
RU2693084C2 (ru) 2019-07-01
CN106103480B (zh) 2021-10-22
CA2936366A1 (en) 2015-07-16
ES2866935T3 (es) 2021-10-20
RU2016132757A3 (es) 2018-07-16
BR112016016020B1 (pt) 2024-02-27
SG10201805934RA (en) 2018-08-30
RU2016132757A (ru) 2018-02-16
EP3092253A4 (en) 2017-11-29
KR102446386B1 (ko) 2022-09-22
NZ722445A (en) 2022-07-01
AU2015204674B2 (en) 2020-09-03
JP6882702B2 (ja) 2021-06-02
US10059764B2 (en) 2018-08-28
JP2020018309A (ja) 2020-02-06
US20160333090A1 (en) 2016-11-17
JP2017503506A (ja) 2017-02-02
RU2019118984A (ru) 2019-08-06
KR20160132006A (ko) 2016-11-16
EP3092253B1 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
MX2020001272A (es) Anticuerpos dirigidos contra interleucina-33 (il-33).
MX2017012429A (es) Anticuerpos dirigidos contra la inmunoglobulina de celulas t y la proteina mucina 3 (tim-3).
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2023001791A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
MX2022002364A (es) Anticuerpos anti-pd-l1.
MX2018015592A (es) Anticuerpos inhibidores de puntos de control biespecificos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
MX2022000112A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
NZ738008A (en) Tigit-binding agents and uses thereof
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2015015037A (es) Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
NZ766356A (en) Anti-pd-1 antibodies
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
NZ724815A (en) Humanized antibodies that bind lgr5
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
WO2015116569A3 (en) Antibodies directed against discoidin domain receptor family, member 1 (ddr1)
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
MX2019002349A (es) Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control.
EA202092572A1 (ru) Композиции и способы обнаружения и лечения рака пищевода